var data={"title":"Dimethyl fumarate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dimethyl fumarate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/542330?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dimethyl-fumarate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dimethyl fumarate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16562890\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Tecfidera</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20504061\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Tecfidera</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16424379\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Fumaric Acid Derivative;</li>\n      <li>\n        Immunomodulator, Systemic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16431773\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Multiple sclerosis (relapsing):</b> Oral: Initial: 120 mg twice daily; after 7 days, increase to the maintenance dose: 240 mg twice daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16431774\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16431775\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16431776\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16431777\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flushing, GI intolerance, or intolerance to maintenance dose: Consider temporary dose reduction to 120 mg twice daily (resume recommended maintenance dose of 240 mg twice daily within 4 weeks). Consider discontinuation in patients who cannot tolerate return to the maintenance dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic injury (suspected drug-induced), clinically significant: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lymphocyte count &lt;500/mm<sup>3 </sup>persisting for &gt;6 months:  Consider treatment interruption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serious infection: Consider withholding treatment until infection resolves.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16562891\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tecfidera: 120 mg, 240 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tecfidera: Capsule, delayed release: 120 mg (14s) and Capsule, delayed release: 240 mg (46s) (60 ea) [contains brilliant blue fcf (fd&amp;c blue #1)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570580\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16431779\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Swallow capsules whole and intact; do not crush, chew, open the capsule, or sprinkle contents on food. Administer with or without food; administering with food may decrease the incidence of flushing. Administration of aspirin (nonenteric coated up to a dose of 325 mg) 30 minutes prior to dimethyl fumarate may also reduce the incidence of flushing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16424331\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Multiple sclerosis:</b> Treatment of patients with relapsing forms of multiple sclerosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16431657\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dimethyl fumarate may be confused with dimethyl sulfoxide</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16431941\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Flushing (40%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (18%), diarrhea (14%), nausea (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (60%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (8%), skin rash (8%), erythema (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Albuminuria (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (9%), dyspepsia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Lymphocytopenia (2% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum AST (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal hepatic function tests, anaphylaxis, angioedema, eosinophilia (transient), progressive multifocal leukoencephalopathy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16431712\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity (eg, anaphylaxis, angioedema) to dimethyl fumarate or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16431713\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatitis/irritation: May cause rash, pruritus, or erythema. There are case reports of contact dermatitis resulting from dimethyl fumarate (DMF) exposure after use as a fungicide and desiccant in the shipping of furniture (Bruze 2011; Gim&eacute;nez-Arnau 2011; Ropper 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Flushing: Commonly causes mild to moderate flushing (eg, warmth, redness, itching, burning sensation); flushing generally appears soon after initiation, and improves or resolves with subsequent dosing. Administration with food may decrease flushing incidence. Administration of aspirin (nonenteric coated &le;325 mg) 30 minutes prior to dimethyl fumarate or a temporary dose reduction may also reduce the incidence and severity of flushing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal events: GI events (eg, nausea, vomiting, diarrhea, abdominal pain, dyspepsia) commonly occur with use; GI events generally occur in the first month of use and decrease thereafter. To improve tolerability, administer with food or temporarily reduce the dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Clinically significant postmarketing cases of hepatic injury have been reported, with an onset ranging from a few days to several months after treatment initiation. Signs/symptoms of hepatic injury, including transaminase elevations &gt;5 times the upper limit of normal (ULN) and total bilirubin elevations &gt;2 times ULN have been observed. Some cases have required hospitalization; however, none of the cases were fatal or resulted in liver failure or transplant. Liver function test abnormalities resolved upon discontinuation. Drug-induced hepatocellular injury resulting in new-onset transaminase elevations combined with increased bilirubin levels is an important predictor of serious hepatic injury that may lead to acute hepatic failure, liver transplant, or death in some patients. Transaminase elevations (usually &lt;3 times ULN) were observed in clinical trials, generally occurring in the first 6 months of treatment. Transaminase elevations &ge;3 times ULN occurred rarely. Monitor liver function tests prior to treatment initiation and during treatment. Discontinue treatment if dimethyl fumarate-induced hepatic injury is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Anaphylaxis and angioedema may occur after the first dose or at any time during treatment. Discontinue therapy if signs and symptoms of anaphylaxis or angioedema occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lymphopenia: Decreased lymphocyte counts may occur. Obtain a CBC, including lymphocyte count, prior to initiation of therapy, after 6 months of treatment, every 6 to 12 months thereafter, and as clinically indicated. Consider therapy interruption in patients with lymphocyte counts &lt;500/mm<sup>3</sup> persisting &gt;6 months and in patients with serious infections. Due to a potential for delayed lymphocyte recovery following treatment interruption or discontinuation, monitor lymphocyte counts until lymphopenia is resolved. The decision to restart dimethyl fumarate should be individualized based on clinical circumstances. Dimethyl fumarate has not been studied in patients with preexisting low lymphocyte counts.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Proteinuria: In clinical trials, proteinuria was reported at a slightly higher incidence than that observed with placebo; significance of these findings is unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Progressive multifocal leukoencephalopathy: Cases of progressive multifocal leukoencephalopathy (PML) due to the JC virus (JCV), including fatality, have been reported, including cases in patients who were not immunocompromised and had no prior exposure to immunocompromised drugs, including natalizumab. The majority of PML cases occurred in patients with lymphocyte counts &lt;500/mm<sup>3</sup> (although the exact role of lymphopenia in PML is unknown). At the first sign or symptom suggestive of PML, perform a diagnostic evaluation and withhold therapy; symptoms progress over days to weeks and may include progressive weakness on one side of the body or clumsiness of limbs, vision disturbances, and mental status changes. Cases of PML have been diagnosed based on MRI findings and the detection of JCV DNA in the CSF without specific PML signs/symptoms. Monitoring with MRI for signs that may be consistent with PML may be beneficial and allow for an early diagnosis of PML.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concomitant drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Dimethyl fumarate should only be prescribed by health care providers who are experienced in the diagnosis and management of multiple sclerosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17917929\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17917927\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=88899&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Dimethyl Fumarate may enhance the adverse/toxic effect of Vaccines (Live). Specifically, Dimethyl Fumarate may increase the risk of vaccinal infection. Dimethyl Fumarate may diminish the therapeutic effect of Vaccines (Live).  Management: Canadian labeling for dimethyl fumarate states that live attenuated vaccine administration is not recommended during treatment.  U.S. labeling does not mention this.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16431709\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Adverse events were observed in animal reproduction studies.</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Women exposed to dimethyl fumarate during pregnancy are encouraged to enroll in the Pregnancy Registry by calling 866-810-1462 or visiting www.tecfiderapregnancyregistry.com.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16431711\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if dimethyl fumarate is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16431781\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC including lymphocyte count (obtained prior to initiation of therapy, after 6 months of treatment, then every 6 to 12 months thereafter and as clinically necessary); liver function tests (transaminases, alkaline phosphatase, total bilirubin) prior to treatment initiation and during treatment as clinically indicated; urinalysis (if proteinuria suspected and/or clinically indicated). Monitor for signs/symptoms of hypersensitivity, infections, and/or progressive multifocal leukoencephalopathy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Anti-JCV antibody and MRI screening for PML as appropriate (Igra 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16431718\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">DMF and its active metabolite, monomethyl fumarate (MMF), have been shown to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, which is involved in cellular response to oxidative stress. The mechanism by which dimethyl fumarate (DMF) exerts a therapeutic effect in MS is unknown, although it is believed to result from its anti-inflammatory and cytoprotective properties via activation of the Nrf2 pathway (Fox, 2012; Gold, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16431720\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: MMF: 53 to 73 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: MMF: 27% to 45%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Undergoes rapid and extensive presystemic hydrolysis by esterases to its active metabolite, monomethyl fumarate (MMF); MMF is further metabolized via the tricarboxylic acid (TCA) cycle. Major serum metabolites include: MMF, fumaric acid, citric acid, and glucose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: MMF: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 2 to 2.5 hours; delayed to 5.5 hours with food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: CO<sub>2</sub> via exhalation (~60%); urine (16%; trace amounts as unchanged MMF), feces (1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20319333\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Tecfidera Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (14): $2,062.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 mg (60): $8,838.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Misc</b> (Tecfidera Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 &amp; 240 mg (60): $8,838.66</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059526\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Skilarence (GB);</li>\n      <li>Tecfidera (AT, AU, BB, BE, BR, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, HK, HR, HU, IE, IL, IS, JP, LT, LU, LV, MT, NL, NO, NZ, PL, PT, QA, RO, SE, SG, SI, SK, TR);</li>\n      <li>Tecpidera (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimethyl-fumarate-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, Second-Generation Fumarate Derivative--Fumapharm/Biogen Idec,&quot; <i>Drugs R D</i>, 2005, 6(4):229-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimethyl-fumarate-drug-information/abstract-text/15991882/pubmed\" target=\"_blank\" id=\"15991882\">15991882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bovenschen HJ, Langewouters AM, and van de Kerkhof PC, &quot;Dimethylfumarate for Psoriasis: Pronounced Effects on Lesional T-cell Subsets, Epidermal Proliferation and Differentiation, but not on Natural Killer T Cells in Immunohistochemical Study,&quot; <i>Am J Clin Dermatol</i>, 2010, 11(5):343-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimethyl-fumarate-drug-information/abstract-text/20553063/pubmed\" target=\"_blank\" id=\"20553063\">20553063</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bruze M and Zimerson E, &quot;Dimethyl Fumarate,&quot; <i>Dermatitis</i>, 2011, 22(1):3-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimethyl-fumarate-drug-information/abstract-text/21291637/pubmed\" target=\"_blank\" id=\"21291637\">21291637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep.</i> 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\"> http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.html</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimethyl-fumarate-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fox RJ, Miller DH, Phillips JT, et al, &quot;Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis,&quot; <i>N Engl J Med</i>, 2012, 367(12):1087-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimethyl-fumarate-drug-information/abstract-text/22992072/pubmed\" target=\"_blank\" id=\"22992072\">22992072</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gim&eacute;nez-Arnau A, &quot;Dimethyl Fumarate: A Human Health Hazard,&quot; <i>Dermatitis</i>, 2011, 22(1):47-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimethyl-fumarate-drug-information/abstract-text/21291643/pubmed\" target=\"_blank\" id=\"21291643\">21291643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gold R, Kappos L, Arnold DL, et al, &quot;Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis,&quot; <i>N Engl J Med</i>, 2012, 367(12):1098-107.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimethyl-fumarate-drug-information/abstract-text/22992073/pubmed\" target=\"_blank\" id=\"22992073\">22992073</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28362522\"></a>Igra MS, Paling D, Wattjes MP, Connolly DJA, Hoggard N. Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.<i> Br J Radiol</i>. 2017;90(1074):20160721. doi: 10.1259/bjr.20160721.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimethyl-fumarate-drug-information/abstract-text/28362522/pubmed\" target=\"_blank\" id=\"28362522\">28362522</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis.</i> 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimethyl-fumarate-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimethyl-fumarate-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ropper AH, &quot;The 'Poison Chair' Treatment for Multiple Sclerosis,&quot; <i>N Engl J Med</i>, 2012, 367(12):1149-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimethyl-fumarate-drug-information/abstract-text/22992079/pubmed\" target=\"_blank\" id=\"22992079\">22992079</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet.</i> 1995;345(8960):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimethyl-fumarate-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tecfidera (dimethyl fumarate) [prescribing information]. Cambridge, MA: Biogen Idec Inc; December 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 88899 Version 84.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F16562890\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F20504061\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F16424379\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F16431773\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F16431774\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16431775\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16431776\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F16431777\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F16562891\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F16570580\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F16431779\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F16424331\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F16431657\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F16431941\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F16431712\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F16431713\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F17917929\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F17917927\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F16431709\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16431711\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F16431781\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F16431718\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F16431720\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F20319333\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059526\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/88899|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dimethyl-fumarate-patient-drug-information\" class=\"drug drug_patient\">Dimethyl fumarate: Patient drug information</a></li></ul></div></div>","javascript":null}